Yes: I was in the petosemtamab / MCLA-158 trial at UCSD from Sept. 27 2023 until March 2024, when the tumors in my neck grew by ~20%: http://jakeseliger.com/202

Yes: I was in the petosemtamab / MCLA-158 trial at UCSD from Sept. 27 2023 until March 2024, when the tumors in my neck grew by ~20%: http://jakeseliger.com/2024/03/18/in-which-the-squamous-cell-carcinoma-tumors-in-my-neck-grow-by-20-in-two-months/ http://jakeseliger.com/2024/03/18/in-which-the-squamous-cell... from January 2024. Between September and January, however, the tumors in my neck shrank by about 20%, which is a startingly good response by R / M HNSCC standards. Perhaps the most interesting question will ultimately be whether oncologists prescribe petosemtamab for patients who get early clean surgical margins, in an effort to prevent recurrence. Oncologists are reluctant to impose chemo-radiation because of chemo's deleterious side effects, but petosemtamab, though it causes rashes, paronychia, and other skin problems.